HeadInvest LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

HeadInvest LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500	Closed	-$228K	–	216
2025 Q3	$228K	Buy	+500	New	+$204K	0.05%	204

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

HeadInvest LLC's ALNY Position: Q4 2025 in Review

HeadInvest LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 500 shares — an estimated $228K sold.

HeadInvest LLC first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $228K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

HeadInvest LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HeadInvest LLC sold 500 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $228K.
HeadInvest LLC first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
HeadInvest LLC's Alnylam Pharmaceuticals position peaked at $228K in Q3 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on HeadInvest LLC's 13F filing for Q4 2025, filed 2 Feb 2026.